Focused On-demand Library for Putative glycosyltransferase 6 domain-containing protein 1

Details

Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


We employ our advanced, specialised process to create targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

PARTNER
Receptor.AI
 
UPACC
Q7Z4J2

UPID:
GL6D1_HUMAN

ALTERNATIVE NAMES:
Galactosyltransferase family 6 domain-containing 1

ALTERNATIVE UPACC:
Q7Z4J2

BACKGROUND:
The protein known as Putative glycosyltransferase 6 domain-containing protein 1, with alternative names including Galactosyltransferase family 6 domain-containing 1, is encoded by a gene represented by the accession Q7Z4J2. The detailed functions of this protein remain to be discovered. Given its classification within the glycosyltransferase family, it is implicated in essential cellular mechanisms, particularly in the enzymatic transfer of sugar molecules to proteins and lipids, which is vital for cell communication and molecular stability.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of Putative glycosyltransferase 6 domain-containing protein 1 holds promise for unveiling new therapeutic avenues. Its role in the enzymatic process of glycosylation suggests its potential impact on understanding and treating disorders associated with abnormal protein and lipid modifications.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.